Skip to main navigation Skip to search Skip to main content

The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells

  • Kelden Richardson
  • , Simon P. Keam
  • , Joe Jiang Zhu
  • , Deborah Meyran
  • , Criselle D’Souza
  • , Sean Macdonald
  • , Kerry Campbell
  • , Michael Robbins
  • , Natalie A. Bezman
  • , Kirsten Todd
  • , Hang Quach
  • , David S. Ritchie
  • , Simon J. Harrison
  • , H. Miles Prince
  • , Joseph A. Trapani
  • , Misty R. Jenkins
  • , Paul A. Beavis
  • , Phillip K. Darcy
  • , Paul J. Neeson
  • Peter Maccallum Cancer Centre
  • University of Melbourne
  • Bristol-Myers Squibb
  • St. Vincent's Hospital Melbourne
  • Royal Melbourne Hospital
  • Walter and Eliza Hall Institute of Medical Research
  • La Trobe University

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells'. Together they form a unique fingerprint.
Sort by

Immunology and Microbiology